Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

Editas Medicine, a prominent genome editing company, will host a conference call and webcast on February 24, 2022, at 8:00 a.m. ET to discuss updates and fourth quarter and full year 2021 results.

Rhea-AI Summary

Editas Medicine, a prominent genome editing company, will host a conference call and webcast on February 24, 2022, at 8:00 a.m. ET to discuss updates and fourth quarter and full year 2021 results. U.S. participants can join by calling 877-407-0989, while international callers should dial 201-389-0921. The event will also be available via live webcast on the company’s website. Editas focuses on using CRISPR technology to develop precision genomic medicines for serious diseases worldwide. For more details, visit Editas Medicine.

Argus Session date unavailable

-0.06% session move Open Argus

Details

News Market Reaction – EDIT

The recorded move for EDIT in the trading session of this news was -0.06%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021.

To access the conference call:

• U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.
• Participants should ask to be connected to the Editas Medicine earnings conference call.
  

A live webcast and replay of the conference call can also be accessed in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Editas Medicine host its next conference call?

Editas Medicine will host its next conference call on February 24, 2022, at 8:00 a.m. ET.

How can I access the Editas Medicine conference call?

To access the conference call, U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921.

What results will Editas Medicine discuss during the conference call?

Editas Medicine will discuss corporate updates and results for the fourth quarter and full year 2021 during the conference call.

Where can I find the webcast for the Editas Medicine conference call?

The webcast for the Editas Medicine conference call can be accessed in the Investors section of their website.

What is the focus of Editas Medicine?

Editas Medicine focuses on developing transformative genomic medicines using CRISPR technology for serious diseases.